Leerink upgraded Wave Life Sciences to Outperform from Market Perform with a price target of $12, up from $5, ahead of clinical data catalysts in the new year in the company’s Huntington’s disease, Duchenne muscular dystrophy and alpha-1-antitrypsin deficiency programs. Wave is “on the cusp of generating data that could de-risk and expand several applications of its RNA chemistry expertise” with these upcoming data sets, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on WVE:
- Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy
- Wave Life Sciences announces initiation of dosing in Phase 2 FORWARD-53 trial
- Wave Life share raise not understood by market, says Mizuho
- Wave Life Sciences 20M share Spot Secondary priced at $5.00
- Wave Life Sciences initiates dosing in the RestorAATion clinical trial program
